Millicent Drug Patent Portfolio
Millicent owns 2 orange book drugs protected by 4 US patents Given below is the list of Millicent's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8268806 | Pharmaceutical compositions | 19 Mar, 2031 | Active |
| US8957054 | Pharmaceutical compositions | 08 Jan, 2030 | Active |
| US8629129 | Pharmaceutical compositions | 07 Aug, 2028 | Active |
| US5855906 | Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors | 19 Dec, 2015 | Expired |
Latest Legal Activities on Millicent's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Millicent.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 06 Feb, 2024 | US8268806 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 21 Jul, 2022 | US8957054 |
|
Withdrawal of Application for PTE
Critical
| 20 Apr, 2022 | US8629129 |
|
Patent Term Extension Certificate
Critical
| 19 Apr, 2022 | US8957054 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 29 Apr, 2021 | US8629129 |
| Notice of Final Determination -Election Required | 12 Mar, 2021 | US8957054 |
| Notice of Final Determination -Election Required | 12 Mar, 2021 | US8629129 |
|
FDA Final Eligibility Letter
Critical
| 13 Oct, 2020 | US8957054 |
|
FDA Final Eligibility Letter
Critical
| 13 Oct, 2020 | US8629129 |
| transaction for FDA Determination of Regulatory Review Period | 20 Feb, 2020 | US8629129 |
| transaction for FDA Determination of Regulatory Review Period | 20 Feb, 2020 | US8957054 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Nov, 2019 | US8268806 |
|
Correspondence Address Change
Critical
| 28 Jan, 2019 | US8957054 |
|
Correspondence Address Change
Critical
| 28 Jan, 2019 | US8629129 |
| Second letter to regulating agency to determine regulatory review period | 09 Jan, 2019 | US8629129 |
Millicent's Family Patents
Millicent Drug List
Given below is the complete list of Millicent's drugs and the patents protecting them.
1. Femring
Femring is protected by 1 patent, which has expired already. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5855906 | Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors |
19 Dec, 2015
(9 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Femring's drug page
2. Intrarosa
Intrarosa is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8268806 | Pharmaceutical compositions |
19 Mar, 2031
(6 years from now)
| Active |
| US8957054 | Pharmaceutical compositions |
08 Jan, 2030
(5 years from now)
| Active |
| US8629129 | Pharmaceutical compositions |
07 Aug, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Intrarosa's drug page